
Alarming study finds that this small difference at birth significantly increases your colorectal cancer risk
Your past might come back to bite you in the butt — literally.
A new study suggests that a key factor in early life could increase your risk of developing colorectal cancer as an adult.
The findings add to a growing body of research trying to pinpoint what's fueling the alarming rise in in colorectal cancer among Americans under 50 over the last three decades.
Advertisement
4 Colorectal cancer refers to cancers of the colon and rectum.
Nadzeya – stock.adobe.com
'Although the relationship between adult body size and colorectal cancer risk is well-documented, the potential influence of measures of body size during early life is less understood,' said Dr. Dieuwertje Kok, associate professor of nutrition and cancer at Wageningen University & Research.
To get to the bottom of it, Kok and her colleagues analyzed 37 studies tracking how weight, height, and body size in childhood and young adulthood could impact your risk of colorectal cancer later in life.
They found that for young adults aged 18 to 25, every five-point increase in body mass index (BMI) above the healthy range raised colon cancer risk by 12%.
Advertisement
For teens between 10 and 19, that risk climbs between 5% and 18%.
Even toddlers aren't safe — a high BMI in kids as young as two was also linked to greater risk.
And here's the kicker: Every extra kilo (2.2 pounds) at birth over 'normal' birth weight — that's 2.5 to 4 kilograms, or 5.51 to 8.82 pounds — was tied to a 9% greater chance of developing colorectal cancer down the road.
Advertisement
'Cancer is a complex disease which develops over several decades, so better understanding of its early origins is critical for more effective prevention efforts and understanding the research gaps,' said Dr. Helen Croker, assistant director of research and policy at World Cancer Research Fund International.
4 Childhood obesity could increase your risk of colorectal cancer as an adult.
íËíâ¬í¸í½í° í©íÆí°í¸í½í° – stock.adobe.com
'The results of this study show that raised body mass index across childhood through young adulthood is an important risk factor for colorectal cancer,' she added.
Advertisement
Colorectal cancer has long been associated with older adults, especially people over 65. But rates among those under 50 have been creeping up since the '90s.
In fact, if you were born between 1981-1996, you face twice the risk of colorectal cancer as compared to people born in 1950, according to the University of California Davis Health.
Scientists suspect that ultra-processed foods and certain diets are major drivers behind the rise in colorectal cancer in young Americans.
One study linked the 'Western diet' — which is high in fat and low in fiber — to an imbalance of gut bacteria, triggering inflammation that ages cells faster and makes them more cancer-prone.
Another found that low calcium intake is tied to one in five colorectal cancer deaths in people 35 and younger.
4 The Western diet is high in calories, sugar, saturated fats and salt.
beats_ – stock.adobe.com
Ultra-processed junk like ice cream, chips, and soda have also been shown to boost the risk and weaken the body's ability to fight the disease.
Advertisement
Our couch potato habits aren't helping. A 2019 study found young adults who watch more than two hours of TV a day have a 70% higher risk of developing colon cancer than those who watch less.
Chronic conditions play a role, too. Research suggests people with nonalcoholic fatty liver disease (NAFLD) — mainly caused by obesity, diabetes, high blood pressure, and high cholesterol — are nearly 24% more likely to get colon cancer.
Inflammatory bowel disease, Crohn's disease and ulcerative colitis have also been shown to increase the risk.
4 More young people are being diagnosed with colorectal cancer than ever before.
New Africa – stock.adobe.com
Advertisement
But here's the scary part: Colorectal cancer is showing up in young, healthy, active people with no obvious risk factors. For them, the culprit might be genetics or hidden environmental triggers.
One study found that a toxin from certain E. coli bacteria called colibactin leaves a unique DNA mark on colon cells in kids exposed to it. These mutations were 3.3 times more common in early-onset cases than in older patients.
In another study, researchers found a fungus called cladosporium — which usually causes skin and nail infections — in the tumors of young colorectal cancer of patients. Scientists aren't sure how it triggers the disease, but it might damage DNA.
Advertisement
A gene called HMGA1 may also hold the answer. Research suggests it acts like a 'key' that turns on DNA regions controlling colon stem cells. When overactivated — due to stress, mutations or poor diet — it can lead to tumor growth and help cancer hide from the immune system.
As scientists race to uncover the causes behind early-onset colorectal cancer, young Americans keep getting diagnosed at alarming rates.
Worse still, young adults tend to be diagnosed later — when the disease is more advanced and the tumors more aggressive.
Advertisement
That's helped make colorectal cancer the leading cause of cancer death in US men under 50, and the second deadliest for women in the same age group.
In response, the US Preventive Services Task Force lowered the recommended screening age from 50 to 45 in 2021 for average-risk adults.
In 2025, the American Cancer Society estimates about 154,270 US adults will be diagnosed with colon or rectal cancer — and roughly 52,900 will die from it.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub
Montreal, Quebec--(Newsfile Corp. - June 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in advanced endosomal escape technologies, is pleased to announce the opening of its first U.S. laboratory in the Boston-Cambridge area. This strategic expansion marks Defence Therapeutics' initial physical presence in the United States, reinforcing its commitment to advancing cutting-edge research and development in one of the world's foremost biotech clusters. The new laboratory, located at Cambridge Scientific Labs in Watertown, will allow Defence Therapeutics to further develop and optimize its proprietary Accum® technology for antibody-drug conjugates ("ADCs"). Establishing a presence in the Boston-Cambridge area provides the company with access to top-tier scientific resources and opportunities for collaboration within the region's renowned biotech ecosystem. The Cambridge Scientific Labs location will serve as a short-term base while Defence Therapeutics evaluates options for a long-term facility in the area. "Our expansion into the Boston-Cambridge area is a significant milestone for Defence Therapeutics," said Sebastien Plouffe, CEO of Defence Therapeutics. "Establishing a U.S. laboratory positions us at the heart of the global biotech community and supports our mission to advance the Accum® platform for next-generation ADCs. We look forward to deepening our presence in the region as we continue to grow and pursue a long-term facility in this dynamic market." About Defence: Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of radio-immuno-conjugate and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against cancer. For further information: Sebastien Plouffe, President, CEO and DirectorP: (514) 947-2272Splouffe@ Cautionary Statement Regarding "Forward-Looking" Information This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change. Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Insider
3 hours ago
- Business Insider
Moderna announces FDA approved mNEXSPIKE, new vaccine against COVID-19
Moderna (MRNA) announced that the U.S. Food and Drug Administration, FDA, has approved mNEXSPIKE, a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for Disease Control and Prevention. 'The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19,' said Stephane Bancel, Chief Executive Officer of Moderna. 'COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. We appreciate the FDA's timely review and thank the entire Moderna team for their hard work and continued commitment to public health.' Confident Investing Starts Here:

Yahoo
3 hours ago
- Yahoo
Umbrella Labs Expands Research Portfolio with Availability of Retatrutide (LY3437943), a Next-Generation Triple Agonist Peptide
TUCSON, AZ / / June 2, 2025 / Umbrella Labs, a leading supplier of advanced research chemicals, announced the expansion of its peptide catalog to include Retatrutide (LY3437943), an investigational triple agonist peptide developed for use in scientific and academic research. This addition marks a significant milestone in the company's commitment to supporting cutting-edge research in metabolic disease, obesity, and type 2 diabetes mellitus (T2DM). Retatrutide has gained attention within the scientific community due to its unique ability to activate three key receptors involved in metabolic regulation: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. This multi-receptor mechanism offers a promising new direction for researchers investigating novel treatments for obesity-related diseases. "We are proud to offer Retatrutide as part of our mission to provide academic and institutional researchers with the most innovative compounds available," said Samuel Yanner, Director of Scientific Operations at Umbrella Labs. "The peptide's clinical and preclinical data demonstrate its potential as a transformative research molecule." Scientific Highlights: Preclinical and Clinical Validation In comparative rodent studies, Retatrutide outperformed GLP-1 monotherapy and the dual agonist Tirzepatide, producing over 30% weight reduction while improving liver lipid profiles, insulin sensitivity, and inflammatory markers (Ma et al., 2025). A Phase 2 human trial led by Jastreboff et al. (2023) demonstrated up to 24.2% weight loss in non-diabetic obese participants, along with significant improvements in blood pressure, fasting glucose, LDL cholesterol, and HbA1c. These outcomes exceed the performance benchmarks of currently approved GLP-1-based therapeutics, including semaglutide. Expanding Research Horizons: Metabolic, Hepatic, and Cardiovascular Implications Retatrutide's diverse effects have fueled interest in multiple areas of academic investigation: Obesity and Weight Management: The triple receptor action mimics metabolic responses seen in bariatric surgery, with non-invasive delivery. T2DM Research: Demonstrated reductions in HbA1c (up to 2.2%) and possible β-cell preservation. NAFLD/NASH Models: Reduction in hepatic fat, ALT/AST normalization, and improved lipid oxidation suggest promising utility. Cardiovascular Metrics: Lower CRP and triglycerides, with HDL elevation, signal potential long-term cardiac benefit. Emerging exploratory areas include microdosing studies in appetite regulation, mitochondrial function, and speculative neuroendocrine roles due to GLP-1 expression in the central nervous system. Commitment to Quality: Umbrella Labs as a Trusted Supplier Retatrutide remains an investigational compound not approved for human use and is offered strictly for in vitro and animal-based research by qualified institutions. Umbrella Labs ensures cGMP-compliant manufacturing, third-party analytical testing, and reliable batch documentation for all peptides. Researchers interested in sourcing Retatrutide can find the compound listed at:Buy Retatrutide (LY3437943) - Umbrella Labs For additional research peptides and SARMs, visit the Umbrella Labs homepage. About Umbrella Labs Umbrella Labs is a premier supplier of research-grade peptides, SARMs, and other investigational compounds used by universities, pharmaceutical developers, and independent research teams. With a focus on purity, testing transparency, and customer support, Umbrella Labs continues to lead the field in supplying next-generation biochemicals for science-driven innovation. Media Contact Samuel YannerDirector of Scientific OperationsUmbrella Labs1-866-289-7276support@ E Hemisphere Loop, Tucson, AZ 85706 References Coskun T, Sloop KW, Loghin C, et al. LY3437943, a Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Improves Metabolic Parameters in Preclinical Models of Obesity. Cell Metab. 2018;28(5):710-722.e10. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Triple-hormone-receptor agonist Retatrutide in adults with obesity: a randomized, double-blind, phase 2 trial. N Engl J Med. 2023;389(13):1134-1145. Ma X, Zhang L, Su Y, et al. Comparative efficacy of GLP-1/GIP/glucagon receptor agonism in diabetic mice: insights into Retatrutide's hepatometabolic benefits. J Endocrinol Invest. 2025;48(1):55-66. Drucker DJ. Advances in oral peptide therapeutics. Nat Rev Drug Discov. 2020;19(4):277-289. Killion EA, Wang J, Yie J, et al. Glucagon receptor activation increases energy expenditure and modulates lipoprotein metabolism in mice. Proc Natl Acad Sci USA. 2018;115(5):E1051-E1060. SOURCE: Umbrella Labs View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data